TCRR News and Press, TCR2 Therapeutics Inc. From 07/27/20

Socket Mobile (NASDAQ: SCKT ) +142%  on launching 2 barcode scanners. More news on: Socket Mobile, Inc., Wilhelmina International, Inc., TCR2 Therapeutics Inc., Stocks on the move, , Read more ...

TCR2 Therapeutics  (NASDAQ: TCRR ) announces positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 trial for mesothelin-expressing solid tumors. More news on: TCR2 Therapeutics Inc., Healthcare stocks news, Read more ... ...

- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients - Two RECIST unconfirmed partial responses and two patients with stable disease through six months       - Manageable toxicity profile, with only one patient exhibiting TC-210-...

TCR 2 Therapeutics (NASDAQ: TCRR ) up  7.6%  AH, in reaction to company's  plans to discuss initial data from the Phase 1 portion of Phase 1/2 trial of its lead drug TC-210, in patients with mesothelin-expressing solid tumors, on Monday. More news on: TCR2 Therape...

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Pha...

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2...

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced an expansion of its leadership team to strengthen e...

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present an e-poster at the American As...

TCR2 Therapeutics (NASDAQ: TCRR ): Q1 GAAP EPS of -$0.65 beats by $0.76 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020 Continued progress of TC-110 with initiation of leading clinical sites participating in Phase 1/2 clinical trial that include Sarah Cannon Resea...